Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical

Drug Profile

Triamcinolone acetonide suprachoroidal injectable suspension - Clearside Biomedical

Alternative Names: CLS - triamcinolone acetonide (TA); CLS-1001; CLS-1003; CLS-TA; ZUPRATA

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Clearside Biomedical
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Uveitis
  • Phase II Retinal oedema
  • Phase I/II Diabetic macular oedema
  • No development reported Ocular inflammation

Most Recent Events

  • 01 Dec 2016 Clearside Biomedical initiates enrolment in a phase III extension trial for Uveitis (associated with macular oedema) in USA (Intraocular) (NCT02952001)
  • 15 Nov 2016 Phase-I/II clinical trials in Diabetic macular oedema (Treatment-experienced, Monotherapy) in USA (Intraocular) (9207190; NCT02949024)
  • 15 Nov 2016 Phase-I/II clinical trials in Diabetic macular oedema (Treatment-naive, Combination therapy) in USA (Intraocular) (9207190; NCT02949024)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top